An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

This study has been completed.
Information provided by:
BioWest Therapeutics Inc Identifier:
First received: February 13, 2006
Last updated: January 17, 2008
Last verified: January 2008
This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection.

Condition Intervention Phase
Hepatitis C, Chronic
Drug: Celgosivir
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks

Resource links provided by NLM:

Further study details as provided by BioWest Therapeutics Inc:

Primary Outcome Measures:
  • Safety analysis
  • HCV viral load reduction from baseline

Estimated Enrollment: 60
Study Start Date: February 2006
Study Completion Date: October 2007

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who completed HCV-05-002 only
  • 18-65 years of age, inclusive
  • Primary diagnosis of chronic HCV infection
  • Non-responders to previous pegylated interferon-based therapy

Exclusion Criteria:

  • Patients naive to interferon-based therapy for chronic HCV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00292084

Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Sponsors and Collaborators
BioWest Therapeutics Inc
Study Director: Jim Pankovich BioWest Therapeutics Inc
  More Information

Responsible Party: Jim Pankovich, MIGENIX Inc. Identifier: NCT00292084     History of Changes
Other Study ID Numbers: HCV-05-004 
Study First Received: February 13, 2006
Last Updated: January 17, 2008
Health Authority: Canada: Health Canada

Keywords provided by BioWest Therapeutics Inc:
Hepatitis C
Genotype 1
End of Treatment Response
Sustained Viral Response

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2b
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 23, 2016